HemaCell

company

About

HemaCell is a new cell therapy company to regenerate hematopoietic lineages in vitro, with unique stem cell reprogramming.

  • Suzhou,Jiangsu,China

Details

Last Funding Type
Series A
Industries
Biotechnology,Pharmaceutical
Founded date
Jun 1, 2021
Operating Status
Active
Legal Name
Suzhou Xueji Biotechnology Co., Ltd.
Also Known As
Xueji Bio

Xueji Bio is a new cell therapy company founded by returnee experts to regenerate hematopoietic lineages (including blood cells and immune cells) in vitro, with unique stem cell reprogramming, editing and differentiation technologies. The company's unique iPSC establishment technology and gene targeting technology can quickly establish a platform using platelet cells as a drug delivery carrier.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
¥100M
HemaCell has raised a total of ¥100M in funding over 2 rounds. Their latest funding was raised on May 27, 2022 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 27, 2022 Series A 7 Detail
Feb 25, 2022 Seed ¥100M 8 CMB International Capital Corporation
Northern Light Venture Capital
Detail